as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹936.8
Change
+22.45 (2.46%)
Open
₹910.0
Prev. Close
₹914.35
Day High
₹939.05
Day Low
₹910.0
Volume Analysis
Traded
450,325
Delivered
209,218
Delivery %
46.46%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (22.3%)
- •Strong operating margin (41.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (3)
- •Strong 3-year EPS growth (15.4%)
- •Strong 3-year revenue growth (26.2%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹976.29 | ₹957.67 | ₹947.24 | ₹928.62 | ₹918.19 | ₹899.57 | ₹889.14 |
| Fibonacci | ₹957.67 | ₹946.57 | ₹939.72 | ₹928.62 | ₹917.52 | ₹910.67 | ₹899.57 |
| Camarilla | ₹944.79 | ₹942.13 | ₹939.46 | ₹928.62 | ₹934.14 | ₹931.47 | ₹928.81 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+46.81%
1 Week
-0.18%
1 Month
+16.29%
3 Months
+7.5%
6 Months
+20.55%
1 Year
+44.69%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹42.36
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
56.66%
Net margin 30.01% × asset turnover 0.87x × equity multiplier 2.17x
Company Overview
Sector
Healthcare
Market Cap
₹51,355 Cr
P/E (TTM)
81.4
ROE
22.3%
Book Value
₹58.2
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Anthem Biosciences Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 75/100. The strongest factor is Financial Strength (100/100), while Valuation (1/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (22.3%); strong operating margin (41.0%); promoter holding is falling. Strong 3-year EPS growth (15.4%).
TopFund Score — Fundamentals Quality
75/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is almost debt free.
- +Company's working capital requirements have reduced from 118 days to 92.3 days
- −Stock is trading at 15.7 times its book value
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Transcript of Q2 & H1 FY27 Earnings Conference Call
Audio recording of Q2/H1 FY2026 earnings call made available on company website.
Newspaper publication on Unaudited Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2026
Investors presentation for the financial results for the quarter and half year ended September 30, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 339 | 525 | 498 | 483 | 540 | 550 | 423 | 611 | 418 | 594 |
| Expenses + | 218 | 330 | 338 | 288 | 349 | 332 | 266 | 344 | 268 | 323 |
| Operating Profit | 121 | 195 | 160 | 195 | 191 | 218 | 157 | 267 | 151 | 271 |
| OPM % | 36.0% | 37.0% | 32.0% | 40.0% | 35.0% | 40.0% | 37.0% | 44.0% | 36.0% | 46.0% |
| Other Income + | 19 | 28 | 24 | 14 | 23 | 48 | 8 | 52 | 25 | 59 |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 | 0 | 2 | 1 | 3 |
| Depreciation | 19 | 20 | 20 | 30 | 26 | 34 | 35 | 40 | 30 | 31 |
| Profit before tax | 118 | 200 | 161 | 178 | 186 | 230 | 130 | 278 | 145 | 296 |
| Tax % | 30.0% | 19.0% | 23.0% | 54.0% | 27.0% | 24.0% | 29.0% | 32.0% | 17.0% | 29.0% |
| Net Profit + | 82 | 162 | 124 | 83 | 136 | 173 | 93 | 190 | 120 | 211 |
| EPS in Rs | 1 | 3 | 2 | 1 | 2 | 3 | 2 | 3 | 2 | 4 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 60 | 5 | -15 | 26 | -23 | 8 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 626 | 633 | 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | 2,124 | 2,046 |
| Expenses + | 454 | 451 | 695 | 666 | 626 | 914 | 1,173 | 1,290 | 1,200 |
| Operating Profit | 172 | 182 | 408 | 565 | 431 | 506 | 672 | 834 | 846 |
| OPM % | 27.0% | 29.0% | 37.0% | 46.0% | 41.0% | 36.0% | 36.0% | 39.0% | 41.0% |
| Other Income + | 21 | 21 | 37 | 49 | 139 | 63 | 85 | 131 | 144 |
| Interest | 18 | 20 | 17 | 10 | 9 | 10 | 11 | 7 | 6 |
| Depreciation | 61 | 62 | 62 | 58 | 64 | 82 | 89 | 134 | 135 |
| Profit before tax | 114 | 121 | 366 | 546 | 497 | 477 | 657 | 824 | 849 |
| Tax % | 32.0% | 23.0% | 26.0% | 26.0% | 23.0% | 23.0% | 31.0% | 28.0% | — |
| Net Profit + | 77 | 93 | 271 | 406 | 385 | 367 | 451 | 592 | 614 |
| EPS in Rs | 1 | 2 | 5 | 7 | 7 | 7 | 8 | 11 | 11 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 19.0% | — |
| Sales growth | — | — | 74 | 12 | -14 | 34 | 30 | 15 | -1 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Reserves | 323 | 413 | 693 | 1,346 | 1,627 | 1,813 | 2,298 | 2,930 | 3,168 |
| Borrowings + | 192 | 159 | 100 | 35 | 126 | 239 | 113 | 54 | 40 |
| Other Liabilities + | 194 | 207 | 232 | 228 | 148 | 235 | 284 | 333 | 365 |
| Total Liabilities | 718 | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 | 3,686 |
| Fixed Assets + | 316 | 306 | 361 | 329 | 449 | 483 | 705 | 783 | 768 |
| CWIP | 12 | 50 | 19 | 154 | 164 | 345 | 297 | 264 | 309 |
| Investments | 73 | 99 | 209 | 273 | 499 | 472 | 433 | 1,007 | 1,261 |
| Other Assets + | 318 | 333 | 445 | 863 | 902 | 1,099 | 1,373 | 1,374 | 1,348 |
| Total Assets | 718 | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 | 3,686 |
| Equity Capital | 8 | 8 | 8 | 9 | 114 | 112 | 112 | 112 | 113 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 196 | 166 | 278 | 333 | 306 | 140 | 271 | 844 |
| Cash from Investing Activity + | -121 | -109 | -196 | -205 | -376 | -221 | -147 | -702 |
| Cash from Financing Activity + | -65 | -48 | -63 | 181 | 64 | -77 | -136 | -40 |
| Net Cash Flow | 9 | 9 | 18 | 308 | -6 | -158 | -12 | 103 |
| Free Cash Flow | 144 | 119 | 159 | 307 | 112 | -156 | 12 | 637 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 114 | 116 | 85 | 81 | 98 | 51 | 64 | 126 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Public | 16.42% | 16.34% | 12.48% | 12.52% | 12.71% |
| Promoters | 74.69% | 74.69% | 74.67% | 71.42% | 71.39% |
| FII | 1.66% | 1.37% | 1.28% | 2.57% | 3.79% |
| DII | 7.21% | 7.6% | 11.55% | 13.48% | 12.1% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Anthem Biosciences Ltd (this stock) | 51,355 | 81.4 | 15.65 | 22.3% |
| Gland Pharma Limited | 53,710 | 42.9 | 5.01 | 10.7% |
| Ipca Laboratories Ltd | 46,508 | 32.3 | 5.36 | 15.7% |
| Glaxosmithkline Pharma Lt | 45,576 | 40.2 | 24.22 | 45.6% |
| Emcure Pharmaceuticals L | 44,370 | 39.9 | 8.29 | 20.1% |
| Biocon Limited. | 58,962 | 86.5 | 1.69 | 1.4% |
| Fortis Healthcare Ltd | 61,047 | 56.9 | 5.81 | 11.2% |
Which Mutual Funds Hold Anthem Biosciences Ltd?
Frequently Asked Questions about Anthem Biosciences Ltd
Anthem Biosciences Ltd (ANTHEM) closed at ₹936.8 on NSE on 19 November 2026, up 22.45 (2.46%) from the previous close.
Anthem Biosciences Ltd trades on the NSE (National Stock Exchange of India) under the symbol ANTHEM.
Anthem Biosciences Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 81.4.
Anthem Biosciences Ltd has a dividend yield of 0.22%.
Anthem Biosciences Ltd's 52-week high is ₹989.0 and its 52-week low is ₹579.0.
Anthem Biosciences Ltd has a market capitalisation of ₹51,355 crore.
Anthem Biosciences Ltd has a TopFund Quality Score of 75/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Anthem Biosciences Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.